John M Dennis1, Beverley M Shields2, Anita V Hill2, Bridget A Knight2, Timothy J McDonald2,3, Lauren R Rodgers1, Michael N Weedon4, William E Henley1, Naveed Sattar5, Rury R Holman6, Ewan R Pearson7, Andrew T Hattersley2, Angus G Jones8. 1. Health Statistics Group, University of Exeter Medical School, Exeter, U.K. 2. National Institute for Health Research Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, U.K. 3. Blood Sciences, Royal Devon and Exeter Hospital, Exeter, U.K. 4. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K. 5. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K. 6. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K. 7. Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, U.K. 8. National Institute for Health Research Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, U.K. angus.jones@exeter.ac.uk.
Abstract
OBJECTIVE: A precision approach to type 2 diabetes therapy would aim to target treatment according to patient characteristics. We examined if measures of insulin resistance and secretion were associated with glycemic response to dipeptidyl peptidase 4 (DPP-4) inhibitor therapy. RESEARCH DESIGN AND METHODS: We evaluated whether markers of insulin resistance and insulin secretion were associated with 6-month glycemic response in a prospective study of noninsulin-treated participants starting DPP-4 inhibitor therapy (Predicting Response to Incretin Based Agents [PRIBA] study; n = 254), with replication for routinely available markers in U.K. electronic health care records (Clinical Practice Research Datalink [CPRD]; n = 23,001). In CPRD, we evaluated associations between baseline markers and 3-year durability of response. To test the specificity of findings, we repeated analyses for glucagon-like peptide 1 (GLP-1) receptor agonists (PRIBA, n = 339; CPRD, n = 4,464). RESULTS: In PRIBA, markers of higher insulin resistance (higher fasting C-peptide [P = 0.03], HOMA2 insulin resistance [P = 0.01], and triglycerides [P < 0.01]) were associated with reduced 6-month HbA1c response to DPP-4 inhibitors. In CPRD, higher triglycerides and BMI were associated with reduced HbA1c response (both P < 0.01). A subgroup defined by obesity (BMI ≥30 kg/m2) and high triglycerides (≥2.3 mmol/L) had reduced 6-month response in both data sets (PRIBA HbA1c reduction 5.3 [95% CI 1.8, 8.6] mmol/mol [0.5%] [obese and high triglycerides] vs. 11.3 [8.4, 14.1] mmol/mol [1.0%] [nonobese and normal triglycerides]; P = 0.01). In CPRD, the obese, high- triglycerides subgroup also had less durable response (hazard ratio 1.28 [1.16, 1.41]; P < 0.001). There was no association between markers of insulin resistance and response to GLP-1 receptor agonists. CONCLUSIONS: Markers of higher insulin resistance are consistently associated with reduced glycemic response to DPP-4 inhibitors. This finding provides a starting point for the application of a precision diabetes approach to DPP-4 inhibitor therapy.
OBJECTIVE: A precision approach to type 2 diabetes therapy would aim to target treatment according to patient characteristics. We examined if measures of insulin resistance and secretion were associated with glycemic response to dipeptidyl peptidase 4 (DPP-4) inhibitor therapy. RESEARCH DESIGN AND METHODS: We evaluated whether markers of insulin resistance and insulin secretion were associated with 6-month glycemic response in a prospective study of noninsulin-treated participants starting DPP-4 inhibitor therapy (Predicting Response to Incretin Based Agents [PRIBA] study; n = 254), with replication for routinely available markers in U.K. electronic health care records (Clinical Practice Research Datalink [CPRD]; n = 23,001). In CPRD, we evaluated associations between baseline markers and 3-year durability of response. To test the specificity of findings, we repeated analyses for glucagon-like peptide 1 (GLP-1) receptor agonists (PRIBA, n = 339; CPRD, n = 4,464). RESULTS: In PRIBA, markers of higher insulin resistance (higher fasting C-peptide [P = 0.03], HOMA2 insulin resistance [P = 0.01], and triglycerides [P < 0.01]) were associated with reduced 6-month HbA1c response to DPP-4 inhibitors. In CPRD, higher triglycerides and BMI were associated with reduced HbA1c response (both P < 0.01). A subgroup defined by obesity (BMI ≥30 kg/m2) and high triglycerides (≥2.3 mmol/L) had reduced 6-month response in both data sets (PRIBA HbA1c reduction 5.3 [95% CI 1.8, 8.6] mmol/mol [0.5%] [obese and high triglycerides] vs. 11.3 [8.4, 14.1] mmol/mol [1.0%] [nonobese and normal triglycerides]; P = 0.01). In CPRD, the obese, high- triglycerides subgroup also had less durable response (hazard ratio 1.28 [1.16, 1.41]; P < 0.001). There was no association between markers of insulin resistance and response to GLP-1 receptor agonists. CONCLUSIONS: Markers of higher insulin resistance are consistently associated with reduced glycemic response to DPP-4 inhibitors. This finding provides a starting point for the application of a precision diabetes approach to DPP-4 inhibitor therapy.
Authors: Zachary T Bloomgarden; Regina Dodis; Catherine M Viscoli; Eric S Holmboe; Silvio E Inzucchi Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Jesse A Berlin; Jill Santanna; Christopher H Schmid; Lynda A Szczech; Harold I Feldman Journal: Stat Med Date: 2002-02-15 Impact factor: 2.373
Authors: A G Jones; R E J Besser; T J McDonald; B M Shields; S V Hope; P Bowman; R A Oram; B A Knight; A T Hattersley Journal: Diabet Med Date: 2011-09 Impact factor: 4.359
Authors: Rachel E J Besser; Johnny Ludvigsson; Angus G Jones; Timothy J McDonald; Beverley M Shields; Bridget A Knight; Andrew T Hattersley Journal: Diabetes Care Date: 2011-02-01 Impact factor: 19.112
Authors: William T Cefalu; Dana K Andersen; Guillermo Arreaza-Rubín; Christopher L Pin; Sheryl Sato; C Bruce Verchere; Minna Woo; Norman D Rosenblum Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Wendy K Chung; Karel Erion; Jose C Florez; Andrew T Hattersley; Marie-France Hivert; Christine G Lee; Mark I McCarthy; John J Nolan; Jill M Norris; Ewan R Pearson; Louis Philipson; Allison T McElvaine; William T Cefalu; Stephen S Rich; Paul W Franks Journal: Diabetologia Date: 2020-09 Impact factor: 10.122
Authors: John M Dennis; Beverley M Shields; Angus G Jones; Ewan R Pearson; Andrew T Hattersley; William E Henley Journal: Clin Epidemiol Date: 2018-12-14 Impact factor: 4.790
Authors: John M Dennis; Beverley M Shields; William E Henley; Angus G Jones; Andrew T Hattersley Journal: Lancet Diabetes Endocrinol Date: 2019-04-29 Impact factor: 44.867
Authors: Abdallah Ahmed Gunaid; Mohammed Mohammed Al-Kebsi; Mahfouth Abdalla Bamashmus; Saleh Ahmed Al-Akily; Ahmed Nasser Al-Radaei Journal: BMJ Open Diabetes Res Care Date: 2018-12-07
Authors: John M Dennis; William E Henley; Michael N Weedon; Mike Lonergan; Lauren R Rodgers; Angus G Jones; William T Hamilton; Naveed Sattar; Salim Janmohamed; Rury R Holman; Ewan R Pearson; Beverley M Shields; Andrew T Hattersley Journal: Diabetes Care Date: 2018-08-02 Impact factor: 19.112